to some people. Sometimes.
A case in point:
Campaigners will hear next month whether their court attempt to overturn a ban on giving people in England and Wales with mild or late-stage Alzheimer's a new class of drugs has been successful.
It is the first-ever court challenge of a decision by the National Institute for Health and Clinical Excellence (Nice).
Nice ruled that only those in the moderate stages of the disease should be prescribed Aricept, Exelon, Reminyl and Ebixa, despite agreeing that they were effective. The drugs, at a cost £2.50 per person per day, were "too expensive".